Psyence Biomedical Ltd.
PBM
$3.92
$0.246.52%
NASDAQ
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.85M | 2.14M | 1.64M | 1.65M | 1.66M |
| Depreciation & Amortization | 2.10K | 1.10K | 200.00 | 100.00 | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.41M | 2.43M | 2.19M | 2.84M | 3.50M |
| Operating Income | -3.41M | -2.43M | -2.19M | -2.84M | -3.50M |
| Income Before Tax | -47.92M | -48.38M | -50.66M | -27.16M | -3.67M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -47.92 | -48.38 | -50.66 | -27.16 | -3.67 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -47.92M | -48.38M | -50.66M | -27.16M | -3.67M |
| EBIT | -3.41M | -2.43M | -2.19M | -2.84M | -3.50M |
| EBITDA | -3.40M | -2.25M | -1.28M | -632.10K | -- |
| EPS Basic | -2.16K | -2.17K | -2.23K | -1.12K | -13.82 |
| Normalized Basic EPS | -59.23 | -41.87 | -25.93 | -17.01 | -8.64 |
| EPS Diluted | -2.16K | -2.17K | -2.23K | -1.12K | -13.82 |
| Normalized Diluted EPS | -59.22 | -41.87 | -25.93 | -17.01 | -8.64 |
| Average Basic Shares Outstanding | 108.40K | 96.10K | 67.20K | 44.80K | 22.40K |
| Average Diluted Shares Outstanding | 108.50K | 96.20K | 67.20K | 44.80K | 22.40K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |